Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Runimotamab in Locally Advanced or Metastatic HER2-Expressing Cancers
NCT03448042Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Jun 2018
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 1, open-label trial of runimotamab in solid tumor, breast cancer, gastric cancer (GC) and 1 more (2 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants with Adverse Events at 78 months. Started Jun 2018; status: active, not recruiting.
02
Drugs
runimotamab
03
Conditions
solid tumorbreast cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03448042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03448042.